New drug cocktail shows promise for untreatable liver cancer
NCT ID NCT07584018
First seen May 15, 2026 · Last updated Jun 08, 2026 · Updated 5 times
Summary
This study tests a combination of three drugs (donafenib, chemotherapy via infusion, and sintilimab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combo can help control the cancer longer. About 90 adults aged 18-80 who have not had prior systemic therapy will take part. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.